Welcome to our dedicated page for Exelixis SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Exelixis, Inc. (EXEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed oncology-focused biopharmaceutical company, Exelixis uses these filings to report material events, financial results, capital allocation decisions and changes in senior leadership.
Form 8-K filings for EXEL include items such as quarterly financial results and corporate updates, stock repurchase program authorizations and executive appointments or departures. For example, Exelixis has filed 8-Ks describing the authorization of a stock repurchase program for up to a specified amount of common stock before a stated date, as well as the appointment of an Executive Vice President, Research and Development and the planned transition of its General Counsel role. These filings complement the company’s earnings press releases by providing structured information on results of operations and significant corporate actions.
Investors and analysts can use Exelixis’ SEC filings to track how the company reports revenue from its cabozantinib franchise, outlines research and development and selling, general and administrative expenses, and communicates guidance ranges for future periods. While detailed financial statements and management discussion are found in periodic reports such as Forms 10-K and 10-Q, current reports on Form 8-K highlight timely developments that may affect the company’s outlook or governance.
On Stock Titan, EXEL filings are accompanied by AI-powered summaries designed to clarify the key points in complex documents. These summaries help readers quickly understand the implications of new filings, from capital return plans to leadership changes, while links to the full text allow for deeper review. The filings page also serves as a starting point for researching topics such as repurchase authorizations, executive transitions and other events that Exelixis has deemed material enough to disclose under SEC rules.
EXEL reports a Form 144 notice proposing sales of common stock. The notice names Morgan Stanley Smith Barney LLC as the broker-dealer and includes numeric entries such as 821,663.76 and 259,708,689 alongside an 02/18/2026 date. The filing also lists two performance share lines dated 01/16/2025 and 02/15/2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting the planned sale of 99,574 Common shares with an aggregate value of $4,382,506.87 on 02/18/2026. The notice lists prior issuances and exercises of Common stock on several dates, including 03/29/2021, 04/01/2019, 05/21/2021, 05/23/2020, and 04/04/2022.
A shareholder of Exelixis filed a notice to sell 42,422 shares of common stock under Rule 144. The shares are expected to be sold on or about 02/17/2026 through NASDAQ, with Morgan Stanley Smith Barney LLC listed as the broker.
These shares were acquired on 02/17/2026 through a stock option exercise from the issuer, paid for in cash, and have an indicated aggregate market value of $1,880,439.99. The filing notes that total shares outstanding are 259,708,689 for context.
A company insider has filed a Form 144 indicating an intent to sell 30,617 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,337,035.20. The shares, classified as performance shares, were acquired from the issuer on 02/15/2026, with the same date listed for payment. The approximate sale date is 02/17/2026 on the NASDAQ market. Over the prior three months, Christopher J. Senner sold 34,278 common shares for $1,473,964.28. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about the issuer.
Exelixis insider Patrick Joseph Haley has filed a notice to sell up to 67,814 shares of the company’s common stock under Rule 144. The planned sale, through Morgan Stanley Smith Barney, has an indicated aggregate market value of $2,951,082.94 based on the figures in the notice.
The shares to be sold were acquired as performance shares from the issuer on January 15, 2026 (37,421 shares) and February 15, 2026 (30,393 shares), with payment listed as not applicable. The notice also shows that Haley previously sold common shares during November 2025 in three transactions totaling tens of thousands of shares, with individual gross proceeds of $1,194,070.94, $421,052.00, and $1,431,757.23.
Exelixis Inc. has a shareholder planning to sell restricted shares under Rule 144. The notice covers 3,856 shares of Exelixis common stock to be sold through UBS Financial Services on NASDAQ, with an approximate aggregate market value of $165,383.84. These shares were acquired as restricted stock units from the issuer on 01/05/2026, the same date listed as the payment date. The filing also reports that Exelixis had 259,708,689 shares of common stock outstanding, providing context for the size of this planned sale.
Exelixis has a planned Rule 144 sale of 34,278 common shares, to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ. The filing lists an aggregate market value of 1,473,964.28 for these shares.
The shares were acquired as performance shares from the issuer on 01/15/2026, with the same date shown for payment and the nature of payment marked "Not Applicable." The document notes 259,708,689 shares outstanding, giving context for the size of this potential sale, and indicates an approximate sale date of 02/13/2026.
A holder filed a notice of proposed sale under Rule 144 to sell 30,250 shares of common stock of the issuer through Morgan Stanley Smith Barney LLC on 02/13/2026 on NASDAQ. The filing shows an aggregate market value of $1,325,407.81 for these planned sales.
The shares were acquired as restricted stock on 05/31/2025 totaling 21,162 shares with no cash payment noted, and 9,088 shares from a stock option exercise on 02/13/2026 paid in cash. Shares outstanding were 259,708,689 at the time indicated.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report beneficial ownership of 13,658,388 shares of Exelixis, Inc. common stock, representing 5.09% of the class. They hold shared power to vote and dispose of these shares, with no sole voting or dispositive power.
The firms state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Exelixis.
Exelixis, Inc. insider plans Rule 144 sale of common stock. A holder has filed to sell 5,000 shares of Exelixis common stock through Morgan Stanley Smith Barney LLC on or around 02/12/2026 on the NASDAQ, with an aggregate market value of $216,250 at the time of the notice.
The shares were received as a gift from an affiliate, identified as Michael Morrissey/Morrissey Family Trust, on 11/11/2025, with the donor having originally acquired them on 10/02/2019. The filing notes 259,708,689 common shares outstanding, providing a baseline for the size of this planned sale.